Intellia Therapeutics Inc. (NTLA)

August 16, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 28

Price Open 27.27

Volume: 566,867

Avg Volume: 645,009

Market Cap: 1.21B

P/E Ratio -13.46

52 Wk Range 15.0601-35.99



NTLA Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
41.66M
6.57M
9.22
15.76%

2018-07-13
41.55M
6.85M
6.33
16.48%

2018-06-29
41.55M
7.32M
6.05
17.61%

2018-06-15
41.55M
5.41M
5.26
13.02%




NTLA Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-01
Q1 2018
N/A
-0.56 (3)
-0.51
0.05

2018-03-14
Q4 2017
N/A
-0.48 (2)
-0.51
0.05

2018-03-13
Q4 2017
N/A
-0.43 (4)
-0.51
0.05

2017-10-31
Q3 2017
N/A
-0.49 (4)
-0.51
0.05

News

The Battle For Best-In-Class In ATTR Has Begun (2018-08-16 11:52 SeekingAlpha)

With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:…

 

FDA and NIH to loosen oversight of gene therapy development (2018-08-16 09:47 SeekingAlpha)

Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study…

 


Statistics

Shares Outstanding: 43.2M

Top 15 Institution Percent: 89.20

Price To Sales: 40.01

Price To Book: 4.17

Revenue: 7.32M

Gross Profit: N/A

Cash: 222.26M

Debt: N/A

Return On Assets: -27.41

Return On Equity: -35.51

Profit Margin: N/A

Price History

Beta: 2.89

50-day Moving Avg: 28.37

200-day Moving Avg: 24.33

YTD Change: 30.17

5-day Change: 1.19

1-month Change: -4.63

3-month Change: 10.72

6-month Change: 11.87

1-year Change: 69.80

Revenue Per Share: 0.00

Revenue Per Employee: 37523.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Intellia Therapeutics Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.intelliatx.com

Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.